Matthew Duffy joins CorMedix board
This article was originally published in Scrip
CorMedix, a pharmaceutical company developing and commercialising therapeutic products for the prevention and treatment of cardiorenal disease, has appointed Matthew Duffy to its board of directors. Having previously worked for Pfizer, MedImmune, and Lev Pharmaceuticals, Mr Duffy is currently a managing partner and founder of Black Diamond Research which provides consulting services to industry.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.